This bill amends Chapter 17, Title 54 of the Idaho Code by adding a new section, 54-1740, which establishes regulations regarding the actions of pharmaceutical manufacturers in relation to the 340B drug pricing program. The new provisions prohibit pharmaceutical manufacturers from denying or interfering with the acquisition and delivery of 340B drugs to contract pharmacies on behalf of covered entities. Additionally, manufacturers are restricted from interfering with pharmacy contracts and cannot require covered entities or contract pharmacies to submit data as a condition for acquiring 340B drugs, except for specific audits related to compliance with federal law.

The bill also includes a severability clause, ensuring that if any part of the section is deemed invalid, the remaining provisions will still stand. Furthermore, it states that if the federal 340B drug pricing program is eliminated, the provisions of this section will become null and void. The act is set to take effect on July 1, 2025, due to an emergency declaration.